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Use of hypnotics in older people with mental illness; a 
systematic study of use in different diagnostic groups  
 
Stephen Curran, Debbie Turner, Shabir Musa, Andrew Byrne,  
John Wattis 
 
Abstract  
Aims The objective of the study was to provide observational clinical data on 
psychotropic drugs and especially hypnotics used in older people with mental illness.  
 
Method This was an observational, single-centre, one-week prevalence study of 
psychiatric symptoms, disorders and psychotropic/hypnotic   drug use in older people 
with mental illness cared for by the South West people Yorkshire Mental Health NHS 
Trust (Wakefield Locality), UK.  
 
Results A total of 593/660 older patients with mental illness (mean±SD age, 76±8.1 
years) were assessed). 44.5% had dementia (excluding vascular dementia) and 
33.7% had a mood disorder. Of the total, 20.4% did not receive CNS active 
medication and 46.2% of patients were prescribed an antidepressant. In total 130 
(21.9%) of patients were prescribed an hypnotic and these were more likely to be 
prescribed to patients with depression (35%) compared with other diagnoses 
(vascular dementia=17.2%, dementia=12.1%, schizophrenia and related 
disorders=21.5% and anxiety disorders=27.3%) (Χ2=36.3, p<0.001). Zopiclone was 
the most commonly prescribed hypnotic accounting for 55% of all hypnotic 
prescriptions and was most commonly prescribed to patients with depression 
(Χ2=30.4, p<0.001).  
 
Conclusions: Hypnotics are commonly used in older people with mental illness 
including depression, dementia, schizophrenia and anxiety disorders. They are 
significantly more likely to be prescribed to patients with depression compared with 
other diagnostic groups and zopiclone was the most commonly prescribed hypnotic 
accounting for 55% of hypnotic prescriptions. Hypnotics were generally well tolerated 
and patients were broadly satisfied with their medication.  
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Introduction 
 
Insomnia is a common complaint affecting approximately one-third of the UK 
population in any one year. It is more common in women, in the elderly and in those 
with psychiatric disorders (Shapiro, 1993). More than 10 million prescriptions for 
hypnotics continue to be dispensed each year in England alone, mostly for 
benzodiazepines and drugs with similar actions such as zaleplon, zolpidem and 
zopiclone (so-called “Z-drugs”) (Department of Health, 2005). Approximately 80% of 
these prescriptions are for those aged 65 years or older (Curran et al., 2003). Despite 
recommendations for short- term use a significant proportion of people remain on 
these drugs for months or even years (Taylor, et al., 1998). 
 
Primary insomnia is defined as a difficulty initiating or maintaining sleep or 
experiencing non-restorative sleep that results in clinically significant distress or 
impairment in functioning (APA, 1994) (Table 1). For a diagnosis of primary 
 
insomnia, the sleep problem cannot be attributed to a medical, psychiatric, or 
environmental cause (such as drug abuse or medications) whereas secondary 
insomnia denotes insomnia due to causes such as these. 
 
Table 1: DSM-IV Diagnostic Criteria for Primary Insomnia  
 
A. Difficulty with initiating or maintaining sleep, or nonrestorative sleep, for at 
least 1 month.  
B. The sleep disturbance (or associated daytime fatigue) causes clinically 
significant distress or impairment in social, occupational, or other important 
areas of functioning.  
C. The sleep disturbance does not occur exclusively during the course of 
narcolepsy, breathing-related sleep disorder, circadian rhythm sleep disorder, 
or a parasomnia.  
D. The disturbance does not occur exclusively during the course of another 
mental disorder (for example, major depressive disorder).  
E. The disturbance is not due to the direct physiological effects of a substance 
(e.g., a drug of abuse, a medication) or a general medical condition. 
 
The cause of insomnia is important as this will influence management and may help 
avoid having to use drug treatments (Maczaj, 1993). Causes of insomnia include 
physiological (e.g. shift-workers and excessive exercise), psychological (e.g. 
distressing life events), psychiatric (e.g. depression, anxiety and dementia), physical 
(e.g. poorly managed pain), pharmacological (e.g. stimulant drugs) and idiopathic 
(primary insomnia) (Wheatley,1986). The risk of primary insomnia increases with age 
and may be related to changes in circadian rhythms also associated with increasing 
age (Bliwise, 1993). 
 
The management of insomnia includes having a clear understanding of the aetiology 
and managing this appropriately. For primary insomnia simple measures should be 
tried first and attention to sleep hygiene (e.g. room temperature, ambient lighting and 
sound levels, diet etc) can be very effective.  Pharmacological treatments should only 
be tried when these simple measures have been tried. The ideal hypnotic would 
induce sleep rapidly, keep patients asleep without disrupting sleep architecture, have 
no adverse effects, produce no next-morning sedation, lack dependence and 
rebound insomnia, and be safe in the medically unwell and in overdose. No drug 
satisfies all these criteria so these drugs need to be used with caution, especially in 
older people. Guidance from national advisory bodies has recommended that 
hypnotics should only be used in the short-term for the treatment of insomnia (Royal 
College of Psychiatrists, 1997, National Institute for Health and Clinical Excellence 
(NICE), 2004, Joint Formulary Committee, 2004). In April 2004, NICE guidance was 
also published on the use of zaleplon, zolpidem and zopiclone for the treatment of 
insomnia (Table 2). 
 
 
Table 2: NICE Guidance on zaleplon, zolpidem and zopiclone for the 
management of insomnia 
 
  
 
 
 
 
 
 
 
 
 
 
 
• NICE recommends that doctors should consider using non-medicine 
treatments, and then, if they think that a hypnotic medicine is the 
appropriate way to treat severe insomnia that is interfering with normal 
daily life, they should prescribe one for only short periods of time and 
strictly according to the licence for the drug.  
 
• Because there is no firm evidence of differences in the effects of zaleplon, 
zolpidem, zopiclone and the shorter-acting benzodiazepines, NICE 
recommends that doctors should prescribe the cheapest drug, taking into 
account the daily dose required and the cost for each dose.  
 
• Treatment should only be changed from one of these hypnotics to another 
if side effects occur that are directly related to the medicine.  
 
• If treatment with one of these hypnotic medicines does not work, the 
doctor should not prescribe one of the others.  
 
Benzodiazepines replaced barbiturates as the main treatment for primary insomnia 
over the past 30 years or so. Although these drugs were initially welcomed, problems 
arose with their indiscriminate use. Hypnotics may be classified in a variety of ways 
and no one approach is universally accepted. However, the classification into 
benzodiazepine and non-benzodiazepine drugs is clinically useful (Hindmarch and 
Currie, 1995). Classification based on half-lives is also clinically meaningful e.g. 
short-acting (oxazepam) and longer acting (nitrazepam). The gamma-aminobutyric 
acid (GABA) receptor is the site of action of most hypnotic drugs (Doble, 1999) but 
classification based on sites/modes of action are not very helpful from a clinical 
perspective Vermeeren, 2004). 
 
A detailed review of hypnotics is beyond the scope of this paper. However, there is a 
good evidence base for hypnotic drug use in younger people but less so in relation to 
older people despite the fact that most prescriptions for hypnotics are for older 
people.  A meta-analysis of 24 randomised controlled trials (involving 2417 
participants) compared potential benefits and risks of short-term treatment with 
sedative hypnotics in people aged 60 years or over with insomnia (Glass 2005). The 
authors concluded that improvements in sleep were statistically significant. However, 
the increased risk of adverse events was also statistically and clinically significant 
including falls and cognitive impairment. The authors queried whether the clinical 
benefits could be justified in view of the prevalence and severity of the adverse 
events. There have also been a number of studies which have focused specifically 
on older people (Barbera 2005; Duran 2005; Melton, 2005; Moen et al 2006; Halas 
2006).  
 
Despite the availability of both established and newer hypnotics for the treatment of 
insomnia, further research is necessary to inform the evidence base for best clinical 
use in older people. The aim of the present study was to provide a better 
understanding of hypnotic drug use in older people with mental illness and 
particularly hypnotic drug use in different diagnostic groups.  
 
 
Method  
 
Study design 
 
This was an observational, single-centre, one week prevalence study of psychiatric 
symptoms, disorders and psychotropic drug use, especially hypnotic drug use carried 
out in the Wakefield District (UK),  South West Yorkshire Mental Health NHS Trust, 
UK over 12 months in 2003/2004. The population in the District consisted of 
aaproximately 55,000 people aged 65 years or older. The service provided for this 
population consisted of two acute wards, one day-hospital, outpatient clinics for three 
consultant teams, three Community Units for the Elderly, and two Community Mental 
Health Teams.  The study was approved by the Wakefield Research Ethics 
Committee. 
 
Patient selection  
 
All consenting patients under the care of psychiatric services for older people in the 
Wakefield District were included in the study. Patients identified from Trust records 
were contacted by a Research Nurse to ask if they would like to take part in the 
study. All patients and caregivers received an information sheet before taking part in 
the study and gave written consent.  
 
Assessments  
 
The Research Nurse undertook a detailed clinical assessment. The clinical 
assessment lasted approximately one hour and included demographic details, history 
of current and previous mental illness, a history of past and current physical illness, 
diagnosis, treatment response (classified as first episode, stable-dissatisfied, stable-
satisfied, treatment resistant, and uncontrolled) and medication use and tolerability. 
In addition drug side-effects were also assessed using the Psychosis Evaluation Tool 
for Common use by Caregivers (PECC) (Lindstrom et al., 1997).  The PECC was 
specifically designed to be used by health care workers including nurses and 
evaluates a range of drug side-effects. The reliability and validity of PECC has been 
described in both younger and older people (de Hert et al., 1999).  
 
The clinical assessment also included an interview with the caregiver, discussions 
with medical and nursing staff and a review of medical notes including GP records. 
This specifically included a review of patients’ current physical health and laboratory 
and other investigations.  
 
Prior to undertaking the study the Research Nurse attended a three-day training 
course to standardise the clinical assessment procedures.   
 
Patients were assessed in a variety of settings including the two acute wards, OP 
clinics, the three Community Units for the Elderly and in their own homes. The 
assessment took approximately one hour to complete and after the assessment a 
copy was made available to the appropriate clinical team. Diagnosis was based on 
DSM-IV criteria (APA, 1994). Some patients attended several parts of the service 
e.g. day hospital and OP clinic but they were only included once.  
 
Side-effects were based on the previous seven days and a standardised protocol 
was used for defining and scoring individual side-effects. Side-effects were measured 
 
on a four-point scale (1=absent; 4=severe, obvious influence on functioning, 
intervention necessary).    
 
Statistical analysis 
 
Statistical analyses were carried out using SAS/STAT software (version 8.12).  
Comparisons of continuous variable used ANOVA, and pair-wise comparisons (Chi 
squared test - χ2, Cochran-Mantel-Haenzel test) for categorical variables were 
performed with adjustment for multiple comparisons employing the Tukey-Kramer’s 
method. 
 
Results  
 
Patient characteristics 
 
Of a total of 660 older patients, 593 (89.8%) patients took part in the study. 293 
patients (approximately 50%) had a diagnosis of dementia with 4.9% of the total 
population having vascular dementia (VaD).  Of the remaining patients 200 (33.7%) 
had an affective disorder and 65 (11%) schizophrenia or a related disorder. In 
addition, the majority of patients had had their mental illness for a relatively short 
mean period – 0.4 years for patients with VaD and 1.7 years for patients with 
schizophrenia and related disorders.   Sixty-nine percent (n=409) of patients were 
female and there were more females (≥67%) in each diagnostic category (χ2, 
p=0.001), with the exception of VaD dementia (males n=19, 65.5%; females n=10, 
34.5%).   
 
Psychoactive drugs 
 
Of the 593 patients, 121 (20.4%) did not receive a psychoactive drug.  A total of 304 
(51.3%) patients were taking an antipsychotic, 274 (46.2%) an antidepressant, 125 
(21.1%) an antidementia drug, 29 (4.7%) an anticonvulsant, 29 (4.9%) anticholinergic 
drug, 42 (7.1%) an anxiolytic and  130 (21.9%) an hypnotic. 
 
Intake of hypnotics 
 
In total 130 (21.9%) of patients were prescribed an hypnotic and these were more 
likely to be prescribed to patients with depression (35%) compared with other 
diagnoses (VaD=17.2%, dementia=12.1%, schizophrenia and related 
disorders=21.5% and anxiety disorders=27.3%) (Χ2=36.3, p<0.001). Zopiclone was 
the most commonly prescribed hypnotic accounting for 55% of all hypnotic 
prescriptions. Zopiclone was most commonly prescribed to patients with depression 
(22%) compared with vascular dementia (10.3%), dementia (5.7%), schizophrenia 
and related disorders (7.7%) and anxiety disorders (15.2%) and these differences 
were significantly different (Χ2=30.4,  p<0.001). The five most commonly prescribed 
hypnotics are listed in Table 3. In addition, one patient was using phenobarbotone 
(long-term) and one patient low dose amitriptyline as hypnotics.  
 
 
 
 
Table 3: The five most commonly prescribed hypnotics in 593 older people 
with mental illness (mean and median doses in mg) 
 
Drug N Mean dose in mg Median dose in mg 
Zopiclone 
 
70 11.9 7.5 
Temazepam 29 13.3 10 
 
Nitrazepam 15 7.2 5 
 
Diazepam 9 5 5 
 
Zolpidem 5 6 5 
 
  
Evaluation of side-effects 
 
There was a statistically significant difference between the different diagnostic  
groups for the mean scores of anticholinergic side-effects (F=2.9, p=0.02) and EPS 
(F=15.6, p<0.001).    Patients with schizophrenia and related disorders had 
significantly higher levels of anticholinergic and EPS side-effects. Hormonal side-
effects were not significantly different between the diagnostic groups (F=0.3, p=0.87).  
 
Hypnotics drugs were generally well tolerated with very few reported side-effects and 
no serious adverse events were recorded. No patient was prescribed medication 
outside BNF recommended doses. Drowsiness the following morning was the most 
common side-effect. This was usually mild but was significantly more likely to occur 
in patients with depression  and the degree of following-morning drowsiness was 
significantly different from other diagnostic groups (ANOVA, F=7.8, p<0.001).  In 
addition, treatment response and patient satisfaction to hypnotic use were rated as 
“satisfied” for the majority of patients (n=121, 93.1%) with 6 patients (4.6%) rated as 
“dissatisfied” and only 3 patients (2.3%) rated as “very dissatisfied”.  
 
Discussion  
 
The use of hypnotics in older people is a relatively neglected area of research 
particularly in clinical populations. The recent NICE publication is welcome but it 
makes no specific mention of hypnotic use in older people and particularly those with 
mental illness.  
 
The principal objective of this study was to obtain a better understanding of the use 
and tolerability of hypnotic drug use in older people with mental illness in the wider 
context of psychotropic drug use and in different psychiatric diagnostic groups.   
 
This study confirms that hypnotics are commonly prescribed to older people with 
mental illness with 21.9% of all patients prescribed one of these drugs. Patients with 
depression were most likely to be prescribed an hypnotic (35%) but patients in other 
diagnostic groups were also commonly prescribed these drugs including vascular 
dementia (17.2%), Alzheimer’s disease (12.1%), schizophrenia and related disorders 
(21.5%) and anxiety disorders (27.3%). In addition, hypnotics were generally well 
tolerated but patients with depression were more likely to experience following-
morning drowsiness compared with other diagnostic groups. This might be because 
 
patients with depression often experience early morning tiredness irrespective of 
hypnotic drug use. The range of hypnotics used was relatively narrow and only five 
were commonly used including zopiclone, temazepam, nitrazepam, diazepam and 
zolpidem. Use of diazepam as an hypnotic was concerning because of its very long 
half-life in older people but evidence for major following-morning drowsiness was not 
found. In addition, the mean dose of diazepam was only 5 mg/day which is relatively 
low. Only one patient was prescribed low dose amitriptyline as an hypnotic and one 
patient continued to take phenobarbitone as an hypnotic. Phenobarbitone  had been 
prescribed for several decades and had been continued because of difficulties 
withdrawing the drug. The use of low dose TCAs has been debated in the 
management of insomnia but the evidence base is very limited and the use of 
tricyclic antidepressants is not generally  recommended for the management of 
insomnia. Reassuringly, no patient was prescribed more than one hypnotic and all 
patients were prescribed within BNF recommended limits. In addition, over 90% of 
patients reported feeling “satisfied” with their hypnotic treatment.  
 
In this study hypnotics were prescribed within BNF limits, side-effects were mild and 
the majority of patients were satisfied with their treatment. Drugs such as diazepam 
should probably be avoided in the management of insomnia because of the potential 
for significant next morning drowsiness. A greater emphasis should be placed on 
identifying treatable causes such as depression combined with patient education and 
sleep hygiene advice. If drugs are used the z drugs are preferable including 
zopiclone, zolpidem and zaleplon butthey should be prescribed only for relatively 
short periods. Unfortunately most of the research in this area has focused on 
younger people. More research specifically in older people with mental illness is 
needed if the management and particularly the pharmacological management of 
insomnia in this neglected group is to gain greater prominence and become more 
evidence based.  
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